O
APLS

OrbiMed’s Apellis Pharmaceuticals APLS Stock Holding History

OrbiMed’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,429,868
Closed -$61M – 113
2025
Q4 		$61M Buy
2,429,868
+106,500
+5% +$2.5M 1.25% 23
2025
Q3 		$52.6M Buy
2,323,368
+841,068
+57% +$19.6M 1.24% 27
2025
Q2 		$25.7M Buy
1,482,300
+50,000
+3% +$926K 0.64% 39
2025
Q1 		$31.3M Buy
+1,432,300
New +$39.6M 0.75% 37
2024
Q4 		– Sell
-1,270,400
Closed -$36.6M – 122
2024
Q3 		$36.6M Sell
1,270,400
-32,400
-2% -$1.2M 0.67% 44
2024
Q2 		$50M Buy
1,302,800
+5,000
+0.4% +$226K 0.99% 32
2024
Q1 		$76.3M Buy
1,297,800
+375,600
+41% +$23.9M 1.4% 25
2023
Q4 		$55.2M Sell
922,200
-338,300
-27% -$17.2M 1.1% 32
2023
Q3 		$47.9M Buy
1,260,500
+350,300
+38% +$15.4M 1.02% 35
2023
Q2 		$82.9M Hold
910,200
– – 1.5% 22
2023
Q1 		$60M Buy
+910,200
New +$52.5M 1.18% 26
2020
Q2 		– Sell
-50,485
Closed -$1.35M – 137
2020
Q1 		$1.35M Buy
+50,485
New +$1.79M 0.02% 129
2019
Q4 		– Sell
-623,859
Closed -$15M – 137
2019
Q3 		$15M Sell
623,859
-1,199,841
-66% -$33M 0.29% 71
2019
Q2 		$46.2M Buy
1,823,700
+61,400
+3% +$1.25M 0.72% 42
2019
Q1 		$34.4M Buy
1,762,300
+1,435,300
+439% +$22.6M 0.53% 51
2018
Q4 		$4.31M Buy
+327,000
New +$5.02M 0.08% 104

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

OrbiMed's APLS Position: Q1 2026 in Review

OrbiMed sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 2,429,868 shares — an estimated $61M sold.

OrbiMed first reported a position in APLS in Q4 2018 and held it in 16 quarters. The position peaked at $82.9M in Q2 2023. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • OrbiMed reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • OrbiMed sold 2,429,868 Apellis Pharmaceuticals shares in Q1 2026, an estimated $61M.
  • OrbiMed first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 16 quarters.
  • OrbiMed's Apellis Pharmaceuticals position peaked at $82.9M in Q2 2023.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.